Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2014 2
2015 1
2016 1
2019 3
2020 1
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
HDAC inhibitors and immunotherapy; a double edged sword?
Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. Kroesen M, et al. Oncotarget. 2014 Aug 30;5(16):6558-72. doi: 10.18632/oncotarget.2289. Oncotarget. 2014. PMID: 25115382 Free PMC article. Review.
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma.
Kroesen M, Büll C, Gielen PR, Brok IC, Armandari I, Wassink M, Looman MW, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ. Kroesen M, et al. Oncoimmunology. 2016 Mar 28;5(6):e1164919. doi: 10.1080/2162402X.2016.1164919. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471639 Free PMC article.
Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
van den Bijgaart RJE, Kroesen M, Wassink M, Brok IC, Kers-Rebel ED, Boon L, Heise T, van Scherpenzeel M, Lefeber DJ, Boltje TJ, den Brok MH, Hoogerbrugge PM, Büll C, Adema GJ. van den Bijgaart RJE, et al. Among authors: kroesen m. J Biol Chem. 2019 Mar 22;294(12):4437-4449. doi: 10.1074/jbc.RA118.002763. Epub 2019 Jan 22. J Biol Chem. 2019. PMID: 30670592 Free PMC article.
Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation.
Kroesen M, Miladinovic V, Hutschemaekers SAJ, Jacobs J, van der Vos C, Wolf AL, Hoogeman MS, van Vulpen M, Bloem JL, P D S Dijkstra S, Peul WC, Penninkhof JJ, Krol ADG. Kroesen M, et al. Radiother Oncol. 2022 Jan;166:58-64. doi: 10.1016/j.radonc.2021.11.020. Epub 2021 Nov 26. Radiother Oncol. 2022. PMID: 34843840 Free article.
HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial.
Elbers JBW, Gunsch PA, Debets R, Keereweer S, van Meerten E, Zindler J, van Norden Y, Hoogeman MS, Verduijn GM, Kroesen M, Nout RA. Elbers JBW, et al. Among authors: kroesen m. BMC Cancer. 2023 Jun 13;23(1):541. doi: 10.1186/s12885-023-11031-w. BMC Cancer. 2023. PMID: 37312053 Free PMC article.
16 results